ASE Technology Holding Co., Ltd. is a Taiwanese corporation ("ASX"), with a principal executive office at 26, Chin 3rd Rd., Nanzih Dist., Kaohsiung, 811, Taiwan, Republic of China. ASE Test, Inc., is a Taiwanese corporation ("ASE Test Taiwan"), with a principal executive office at 10, West 5th Street, Nanzih Dist., Kaohsiung, 811, Taiwan.

The principal business of ASX includes semiconductor packaging, design and production of interconnect materials, front-end engineering testing, wafer probing, and final testing services, as well as electronic manufacturing services. The principal business of ASE Test Taiwan is providing semiconductor testing services.

During the last five years, none of the Reporting Persons nor any director or executive officer of the Reporting Persons have been convicted in a criminal proceeding.

During the last five years, none of the Reporting Persons nor any director or executive officer of Reporting Persons was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

The Reporting Persons are organized in Taiwan, Republic of China.

All of the conversion price and share number information below gives effect to the June 2025 Reverse Split. On March 10, 2025, ASE Test Taiwan entered into the 2023 Agreement Amendment with the Issuer, which amended and modified the 2023 Agreement pursuant to which ASE Test Taiwan committed to pay a total aggregate amount of $2,000,000 to the Issuer in exchange for convertible promissory note(s). The 2023 Agreement Amendment amended and modified the term and conversion price of the 2023 Agreement. Following the amendment, the note bears 6% compound interest and matures on March 12, 2027. The note will be convertible into shares of Common Stock at a conversion price equal to the lower of (a) $37.50 per share and (b) the higher of (x) the average closing price per share for the period of thirty (30) trading days prior to the day when ASE Test Taiwan exercises the conversion right or (y) $22.50 per share (or 105,868 shares), subject to anti-dilutive adjustment as set forth in the note. On May 3, 2024, ASE Test Taiwan entered into the 2024 Agreement pursuant to which ASE Test Taiwan purchased from the Issuer a Convertible Note in the aggregate principal amount of $9,000,000. The note bears 6% compound interest and has a three-year term. The note will be convertible into shares of Common Stock at a conversion price of $22.50 per share (or 449,440 shares), subject to customary anti-dilution adjustments. As part of the 2024 Agreement, ASE Test Taiwan received a five-year common stock purchase warrant which vested and became exercisable following a six-month period from the date of issue. The warrant may be exercised for up to 100,000 shares of Common Stock at a price of $22.50 per share, customary to anti-dilution adjustments. The purchase of the Convertible Note was funded by ASE Test Taiwan with cash on hand.

The purpose of the acquisition was to make a financial investment in the Issuer. The Reporting Persons may engage in discussions with management, the board of directors of the Issuer (the "Board"), other shareholders of the Issuer and other relevant parties concerning the business, assets, capitalization, financial condition, operations, management, strategy, potential business combinations and strategic alternatives, and future plans of the Issuer. The Reporting Persons also may consider, formulate, discuss and seek to cause the Issuer to implement various plans or proposals intended to protect, preserve or enhance stockholder value or protect, preserve or enhance the value of the Issuer's assets, including plans or proposals that may involve extraordinary matters relating to the Issuer. Any such actions or transactions may be taken, advocated by, or involve the Reporting Persons alone or in conjunction with other shareholders, financing sources and/or other third parties, and could include proposing or considering one or more of the actions described in subsections (a) through (j) of Item 4 of Schedule 13D. The Reporting Persons intend to review their investments in the Issuer on a continuing basis. Depending on various factors, including, without limitation, the Issuer's financial position and strategic direction, actions taken by the Board, price levels of shares of the Common Stock, other investment opportunities available to the Reporting Persons, concentration of positions in the portfolios managed by the Reporting Persons, market conditions and general economic and industry conditions, the Reporting Persons may take such actions with respect to their investment in the Issuer as they deem appropriate, including, without limitation, purchasing additional shares of the Common Stock or other financial instruments related to the Issuer or the Common Stock or selling some or all of the Common Stock, engaging in hedging or similar transactions involving securities relating to the Issuer or the Common Stock and/or otherwise changing their intention with respect to any and all matters referred to in subsections (a) through (j) of Item 4 of Schedule 13D.

The responses of each of the Reporting Persons with respect to Rows 11 and 13 of the cover pages of this Schedule 13D that relate to the aggregate number and percentage of Ordinary Shares are incorporated herein by reference. The responses of each of the Reporting Persons with respect to Rows 7, 8, 9 and 10 of the cover pages of this Schedule 13D that relate to the number of Ordinary Shares as to which such Reporting Persons have sole or shared power to vote, or to direct the vote, and sole or shared power to dispose of, or to direct the disposition, are incorporated herein by reference.

See (a).

Except as reported in Item 3 above, the Reporting Persons have not affected any transactions in the shares of Common Stock in the sixty days prior to the date hereof.

The information in Item 2 is incorporated by reference into this Item 5(d).

Not applicable.

The Reporting Persons' responses to Items 3 - 5 are incorporated by reference into this Item 6. All of the conversion price and share number information below gives effect to the June 2025 Reverse Split. ASE Test Taiwan directly holds 11,777 shares of Common Stock. On March 13, 2023, the Issuer entered into the 2023 Agreement with ASE Test Taiwan pursuant to which ASE Test Taiwan committed to pay a total aggregate amount of $2,000,000 to the Issuer in exchange for convertible promissory note(s) in three tranches in the amounts of $1,000,000 (the "First Tranche"), $500,000 (the "Second Tranche"), and $500,000 (the "Third Tranche") conditioned, among other things, on the Issuer achieving certain business milestones. ASE Test Taiwan provided $1,500,000 on as April 12, 2023 and the remaining $500,000 on September 12, 2023. The convertible note(s) issued under the 2023 Agreement were originally set to mature on March 13, 2025. On March 10, 2025, the Issuer and ASE Test Taiwan entered the 2023 Agreement Amendment, which amended and superseded the term and conversion price of the 2023 Agreement. Accordingly, ASE Test Taiwan holds a convertible note that will mature on March 12, 2027 and bears interest at the rate of 6% compounded interest per annum. At any time after the issuance and before the maturity date, the note is convertible into the Issuer's Common Stock at a conversion price equal to the lower of (a) $37.50 per share and (b) the higher of (x) the average closing price per share for the period of thirty (30) trading days prior to the day when ASE Test Taiwan exercises the conversion right or (y) $22.50 per share (or 105,868 shares), subject to anti-dilutive adjustment as set forth in the note. On May 3, 2024, ASE Test Taiwan entered into a Convertible Note and Warrant Purchase Agreement with the Issuer (the "2024 Agreement") pursuant to which ASE Test Taiwan purchased from the Issuer a Convertible Note in the aggregate principal amount of $9,000,000. The note bears 6% compound interest and has a three-year term. The note will be convertible into shares of Common Stock at a conversion price of $22.50 per share (or 449,440 shares), subject to customary anti-dilution adjustments. As part of the 2024 Agreement, ASE Test Taiwan received a five-year common stock purchase warrant which vested and became exercisable following a six-month period from the date of issue. The warrant may be exercised for up to 100,000 shares of Common Stock at a price of $22.50 per share, customary to anti-dilution adjustments. Effective May 3, 2024, Ainos Inc., a Cayman Islands corporation ("Ainos KY") and ASE Test Taiwan entered into a voting agreement with respect to the voting stock of the Issuer (the "Voting Agreement"). Pursuant to the Voting Agreement, ASE Test Taiwan has agreed to vote all of its current or future acquired voting stock of the Issuer in the manner determined by Ainos KY in its sole discretion. The Voting Agreement continued in effect until May 3, 2025 and was subsequently automatically renewed for an additional one-year period until May 3, 2026; thereafter, it will automatically renew for additional one-year periods unless ASE Test Taiwan provides prior notice of termination. As part of the Voting Agreement, ASE Test Taiwan agreed that, without Ainos KY's written consent, it would not sell or transfer more than 20% of its shares of the Issuer in any calendar year period through the fifth anniversary of the date of the Voting Agreement. If, in any calendar year, ASE Test Taiwan does not sell the full 20% allocation, the remaining percentage will be added to and increase the following year's allocation. The transfer restrictions will terminate upon the termination of the Voting Agreement. Except as set forth herein, neither of the Reporting Persons has any contracts, arrangements, understandings or relationships (legal or otherwise) with any person with respect to any securities of the Issuer, including but not limited to any contracts, arrangements, understandings or relationships concerning the transfer or voting of such securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or losses, or the giving or withholding of proxies.

1 Joint Filing Agreement dated as of April 15, 2026 by and among the Reporting Persons. 2.1 Convertible Promissory Note Purchase Agreement, dated March 13, 2023, by and between the Issuer and ASE Test Taiwan in the principal amount of $2,000,000 (incorporated by reference to Exhibit 2.1 to the Schedule 13D filed by ASE Test Taiwan on May 8, 2024). 2.2 Convertible Promissory Note, dated May 3, 2024, issued by the Issuer in favor of ASE Test Taiwan in the principal amount of $9,000,000 (incorporated by reference to Exhibit 4.2 to the Issuer's Current Report on Form 8-K filed on May 7, 2024). 2.3 Common Stock Warrant, dated May 3, 2024, issued by the Issuer to ASE Test Taiwan (incorporated by reference to Exhibit 4.3 to the Issuer's Current Report on Form 8-K filed on May 7, 2024). 2.4 Convertible Note and Warrant Purchase Agreement, dated May 3, 2024, by and between the Issuer and ASE Test Taiwan (incorporated by reference to Exhibit 10.1 to the Issuer's Current Report on Form 8-K on May 7, 2024). 2.5 Voting Agreement, dated May 3, 2024, by and between Ainos KY and ASE Test Taiwan (incorporated by reference to Exhibit 4.1 to the Issuer's Current Report on Form 8-K on May 7, 2024). 2.6 Amendment to Convertible Promissory Note, dated March 10, 2025, by and between the Issuer and ASE Test Taiwan (incorporated by reference to Exhibit 10.1 to the Issuer's Current Report on Form 8-K on March 11, 2025). 99.A Schedule A